## **Burkhard Hirsch**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7283405/publications.pdf

Version: 2024-02-01

	840776		940533
15	597	11	16
papers	citations	h-index	g-index
16	16	16	1091
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	c-FLIP Mediates Resistance of Hodgkin/Reed-Sternberg Cells to Death Receptor–induced Apoptosis. Journal of Experimental Medicine, 2004, 199, 1041-1052.	8.5	187
2	Deep Sequencing of MYC DNA-Binding Sites in Burkitt Lymphoma. PLoS ONE, 2011, 6, e26837.	2.5	90
3	CD30-Induced Signaling Is Absent in Hodgkin's Cells but Present in Anaplastic Large Cell Lymphoma Cells. American Journal of Pathology, 2008, 172, 510-520.	3.8	65
4	Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group. British Journal of Cancer, 2015, 113, 1704-1711.	6.4	61
5	Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation. Journal of Pathology, 2003, 200, 214-221.	4.5	44
6	Induction of the inflammatory regulator <scp>A</scp> 20 by gibberellic acid in airway epithelial cells. British Journal of Pharmacology, 2016, 173, 778-789.	5.4	28
7	Resistance of Cutaneous Anaplastic Large-Cell Lymphoma Cells to Apoptosis by Death Ligands Is Enhanced by CD30-Mediated Overexpression of c-FLIP. Journal of Investigative Dermatology, 2010, 130, 826-840.	0.7	24
8	cIAP2 is highly expressed in Hodgkin–Reed–Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3. Journal of Molecular Medicine, 2006, 84, 132-141.	3.9	22
9	Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 557-565.	2.8	19
10	Antibody-based delivery of tumor necrosis factor (L19-TNF $\hat{l}_{\pm}$ ) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model. Journal of Cancer Research and Clinical Oncology, 2018, 144, 499-507.	2.5	16
11	A novel A20 (TNFAIP3) antibody (Berâ€A20) can be used to detect unmutated <i>A20</i> by immunohistology. Histopathology, 2012, 60, E19-27.	2.9	12
12	Anti-CD30 Human IL-2 Fusion Proteins Display Strong and Specific Cytotoxicity In Vivo. Current Drug Targets, 2009, 10, 110-117.	2.1	11
13	Galectin-1-mediated cell death is increased by CD30-induced signaling in anaplastic large cell lymphoma cells but not in Hodgkin lymphoma cells. Laboratory Investigation, 2012, 92, 191-199.	3.7	9
14	RIP1 expression is necessary for CD30-mediated cell death induction in anaplastic large-cell lymphoma cells. Laboratory Investigation, 2013, 93, 677-689.	3.7	5
15	Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2020, 60, 87-96.	0.8	1